Overcoming therapeutic resistance in driver-negative NSCLC: Immunomodulatory mechanisms and clinical efficacy of Camrelizumab-chemotherapy combination in a real-world cohort

Abstract Background Driver gene-negative advanced non-squamous non-small cell lung cancer (NSCLC) exhibits inherent resistance to conventional therapies, representing a significant treatment challenge. The limited efficacy of platinum-based chemotherapy alone underscores the need for resistance-miti...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Yan Ge, Yang Zhao
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Springer 2025-06-01
Ráidu:	Discover Oncology
Fáttát:	NSCLC Camrelizumab Treatment resistance Immunomodulation PD-1 Inhibition Chemoimmunotherapy
Liŋkkat:	https://doi.org/10.1007/s12672-025-02926-0
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!